JP2019504865A5 - - Google Patents

Download PDF

Info

Publication number
JP2019504865A5
JP2019504865A5 JP2018542754A JP2018542754A JP2019504865A5 JP 2019504865 A5 JP2019504865 A5 JP 2019504865A5 JP 2018542754 A JP2018542754 A JP 2018542754A JP 2018542754 A JP2018542754 A JP 2018542754A JP 2019504865 A5 JP2019504865 A5 JP 2019504865A5
Authority
JP
Japan
Prior art keywords
ethanol
room temperature
solution
dihydrophthalazine
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018542754A
Other languages
English (en)
Other versions
JP6949856B2 (ja
JP2019504865A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/000209 external-priority patent/WO2017140422A1/en
Publication of JP2019504865A publication Critical patent/JP2019504865A/ja
Publication of JP2019504865A5 publication Critical patent/JP2019504865A5/ja
Application granted granted Critical
Publication of JP6949856B2 publication Critical patent/JP6949856B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (5)

  1. 5−アミノ−2,3−ジヒドロフタラジン−1,4−ジオンの結晶形の製造方法であって、
    以下の工程:
    a)5−アミノ−2,3−ジヒドロフタラジン−1,4−ジオンを、50〜100℃で5:1〜1:1(v/v)の範囲のエタノール−水還流溶液に溶解する工程、
    b)前記溶液を60〜240分間かけて室温に冷却する工程、
    c)沈殿した結晶生成物を分離する工程、
    d)前記結晶生成物を室温で6〜48時間かけて乾燥させる工程、
    を含み、
    得られた結晶形が、粉末X線回折によって決定された以下の結晶学値:
    d値:11.4;11.2;6.9;6.8;6.4;5.6;3.6;3.5;3.5;3.3;3.2および
    2θ値:7.8;7.9;12.8;13.0;13.9;15.7;24.9;25.7;25.7;27.2;27.5
    によって特徴付けられる
    方法。
  2. 前記得られた結晶形が0.4%以下の結晶含水量を有する、
    請求項1に記載の方法。
  3. 前記エタノールが98%以上の純度を有する、
    請求項1又は2に記載の方法。
  4. 請求項1から3のいずれか1項に記載の方法であって,
    e)前記d)工程の後に、得られた結晶形をエタノール中に1〜3回再懸濁し、撹拌し、エタノールで再洗浄し、再び乾燥させる工程をさらに含む方法。
  5. 前記a)〜d)の工程が、それぞれ:
    a)5−アミノ−2,3−ジヒドロフタラジン−1,4−ジオンをエタノール−水還流溶液(3:1、v/v)に80℃で溶解する工程、
    b)前記溶液を120分間かけて室温に冷却する工程、
    c)沈殿した結晶生成物を分離する工程、および
    d)前記結晶生成物を室温で12時間乾燥させる工程である、
    請求項1から4のいずれか一項に記載の方法。
JP2018542754A 2016-02-16 2017-02-15 5−アミノ−2,3−ジヒドロフタラジン−1,4−ジオンの結晶形の製造方法 Active JP6949856B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16000380.2 2016-02-16
EP16000380 2016-02-16
PCT/EP2017/000209 WO2017140422A1 (en) 2016-02-16 2017-02-15 Method for producing a crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione

Publications (3)

Publication Number Publication Date
JP2019504865A JP2019504865A (ja) 2019-02-21
JP2019504865A5 true JP2019504865A5 (ja) 2020-03-26
JP6949856B2 JP6949856B2 (ja) 2021-10-13

Family

ID=55361317

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018542754A Active JP6949856B2 (ja) 2016-02-16 2017-02-15 5−アミノ−2,3−ジヒドロフタラジン−1,4−ジオンの結晶形の製造方法

Country Status (8)

Country Link
US (1) US11203575B2 (ja)
EP (1) EP3416952B1 (ja)
JP (1) JP6949856B2 (ja)
KR (1) KR102535959B1 (ja)
CN (1) CN109071461B (ja)
CA (1) CA3011766C (ja)
ES (1) ES2796476T3 (ja)
WO (1) WO2017140422A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3511325A1 (en) * 2018-01-11 2019-07-17 MetrioPharm AG Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione
US20210379063A1 (en) * 2018-10-26 2021-12-09 Immunopharma Plus D.O.O. Oral aminodihydrophthalazinedione compositions and their use in the treatment of non-viral hepatitis
KR20220158030A (ko) * 2020-03-25 2022-11-29 메트리오팜 아게 급성 폐손상 치료용 5-아미노-2,3-디히드로-1,4-프탈라진디온
IL298899A (en) * 2020-06-10 2023-02-01 Metriopharm Ag A compound for the treatment of corona virus infections
CA3202852A1 (en) * 2020-12-01 2022-06-09 Reverspah Llc Methods and compositions for treating chronic obstructive pulmonary disease, asthma, pneumonia, bronchitis, cystic fibrosis and pulmonary edema, interstitial lung disease, sarcoidosis, idiopathic pulmonary fibrosis, a cute respiratory distress syndrome, and pulmonary arterial hypertension
WO2022117221A1 (en) * 2020-12-02 2022-06-09 Metriopharm Ag Luminol for the prophylaxis and the treatment of sequelae of a sars-cov-2 infection

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743541A (en) * 1985-07-17 1988-05-10 Mast Immunosystems, Inc. Luminescent substrate preparation and its use in specific binding assays
FR2839155B1 (fr) * 2002-04-25 2005-02-04 Roc Imp Procede pour detecter et localiser des traces de sang et compose pour detecter des traces de sang
BRPI0307864B1 (pt) * 2003-11-25 2016-01-12 Univ Rio De Janeiro processo para formação de hidrazidas a partir de hidrazinas e ácido dicarboxílicos
CN100390152C (zh) * 2006-03-23 2008-05-28 潘健 一种合成3-硝基或3-氨基邻苯二甲酰肼的方法
PL231885B1 (pl) * 2009-01-16 2019-04-30 Abidopharma Spolka Z Ograniczona Odpowiedzialnoscia Sposób wytwarzania soli 5-amino-2,3-dihydroftalazyno-1,4-di onu z metalami alkalicznymi, ich kompozycje farmaceutyczne i ich zastosowanie
CH704794B1 (de) * 2010-03-01 2013-04-15 Metriopharm Ag Kristalline Form zu 5-Amino-2,3-dihydrophthalazin-1,4-dion Natriumsalz, diese enthaltende pharmazeutische Zubereitungen und Verfahren zu ihrer Herstellung.
WO2011123776A2 (en) * 2010-04-01 2011-10-06 Guthery B Eugene Method for detecting occult blood
US20110246075A1 (en) * 2010-04-01 2011-10-06 Banik Niranjan C Providing a Transform Function to Produce a Mechanical Property of a Subterranean Structure

Similar Documents

Publication Publication Date Title
JP2019504865A5 (ja)
JP2018024682A5 (ja)
JP2018035160A5 (ja)
JP2017222697A5 (ja)
JP2015063536A5 (ja)
JP2014221842A5 (ja)
JP2015044837A5 (ja)
JP2009120624A5 (ja)
JP2010533203A5 (ja)
JP2018505199A5 (ja)
JP2019504103A5 (ja)
JP2011513485A5 (ja)
JP2019505533A5 (ja)
JP2009531465A5 (ja)
JP2019505532A5 (ja)
JP2012500819A5 (ja)
JP2018538331A5 (ja)
JP2018522945A5 (ja)
RU2016118796A (ru) Новая кристаллическая форма 2-{ 3-[2-(1-{ [3, 5-бис(дифторметил)-1н-пиразол-1-ил]ацетил} пиперидин-4-ил)-1, 3-тиазол-4-ил]-4, 5-дигидро-1, 2-оксазол-5-ил} -3-хлорфенилметансульфоната
JP2017210488A5 (ja)
JP2009540007A5 (ja)
JP2013528668A5 (ja)
AR081267A1 (es) Procedimiento de obtencion de la forma cristalina a del febuxostat
JP2018502165A5 (ja)
JP2015515271A5 (ja)